Updated January 25,2024 : Texas Medicaid Preferred Drug List Updates
Date: 02/02/24
The Texas Health and Human Services Commission (HHSC), published the semi-annual update of the Texas Medicaid Preferred Drug List (PDF) on Thursday January 25, 2024. The update is based on changes presented at the Vendor Drug Program (VDP) Drug Utilization Review (DUR) Board meeting in October 2023. Superior HealthPlan follows the Texas Medicaid Vendor Drug Formulary and the PDL.
DRUG CLASS | DRUG NAME | CURRENT | STATUS CHANGE ON 1/25/24 |
|---|---|---|---|
ANTIPSYCHOTICS | ABILIFY ASIMTUFII (INTRAMUSCULAR) | Not Rated | Non-preferred |
ANTIPSYCHOTICS | CAPLYTA (ORAL) | Non-preferred | Preferred |
ANTIPSYCHOTICS | INVEGA HAFYERA (INTRAMUSCULAR) | Preferred | Non-preferred |
ANTIPSYCHOTICS | LURASIDONE (ORAL) | Non-preferred | Preferred |
ANTIPSYCHOTICS | LATUDA (ORAL) | Preferred | Non-preferred |
COLONY STIMULATING FACTORS | UDENYCA AUTOINJECTOR (SUBCUTANEOUS) | Not Rated | Non-preferred |
EPINEPHRINE, SELF INJECTED | AUVI-Q 0.1MG (INTRAMUSCULAR) | Not Rated | Preferred |
EPINEPHRINE, SELF INJECTED | AUVI-Q 0.15MG (INTRAMUSCULAR) | Non-preferred | Preferred |
EPINEPHRINE, SELF INJECTED | AUVI-Q 0.3MG (INTRAMUSCULAR) | Non-preferred | Preferred |
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS | JANUMET XR (ORAL) | Non-preferred | Preferred |
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS | JENTADUETO XR (ORAL) | Non-preferred | Preferred |
HYPOGLYCEMICS, SGLT2 | INPEFA (ORAL) | Not Rated | Non-preferred |
HYPOGLYCEMICS, SGLT2 | INVOKAMET XR (ORAL) | Non-preferred | Preferred |
MACROLIDES | ERYPED 200 SUSPENSION (ORAL) | Preferred | Non-preferred |
MACROLIDES | ERYTHROMYCIN ETHYLSUCCINATE 200 SUSPENSION (ORAL) | Non-preferred | Preferred |
NSAIDS | CELECOXIB (AG) (ORAL) | Non-preferred | Preferred |
NSAIDS | CELECOXIB (ORAL) | Non-preferred | Preferred |
OPHTHALMIC ANTIBIOTICS | MOXIFLOXACIN (AG) (VIGAMOX) (OPHTHALMIC) | Non-preferred | Preferred |
OPHTHALMIC ANTIBIOTICS | MOXIFLOXACIN (VIGAMOX) (OPHTHALMIC) | Non-preferred | Preferred |
OPHTHALMIC ANTIBIOTICS | VIGAMOX (OPHTHALMIC) | Preferred | Non-preferred |
The tables below summarize some of the anticipated noteworthy changes from the October 2023 DUR meetings. Please note: The tables are not the complete list of changes. Please reference the Texas Medicaid PDL for a complete list of recommended medications or visit DUR Board webpage on the Texas Vendor Drug website for all decisions.